key: cord-1056068-zp5c4sni authors: Trimpert, Jakob; Dietert, Kristina; Firsching, Theresa C.; Ebert, Nadine; Nhu Thao, Tran Thi; Vladimirova, Daria; Kaufer, Susanne; Labroussaa, Fabien; Abdelgawad, Azza; Conradie, Andelé; Höfler, Thomas; Adler, Julia M.; Bertzbach, Luca D.; Jores, Joerg; Gruber, Achim D.; Thiel, Volker; Osterrieder, Nikolaus; Kunec, Dusan title: Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding date: 2021-07-20 journal: Cell Rep DOI: 10.1016/j.celrep.2021.109493 sha: 216f7bb26af60fce344e7089deb4eb006c7e9387 doc_id: 1056068 cord_uid: zp5c4sni Safe and effective vaccines are urgently needed to stop the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We constructed a series of live attenuated vaccine candidates by large-scale recoding of the SARS-CoV-2 genome, and assessed their safety and efficacy in Syrian hamsters. Animals were vaccinated with a single dose of the respective recoded virus and challenged 21 days later. Two of the tested viruses did not cause clinical symptoms, but were highly immunogenic and induced strong protective immunity. Attenuated viruses replicated efficiently in the upper but not in the lower airways, causing only mild pulmonary histopathology. After challenge, hamsters developed no signs of disease and rapidly cleared challenge virus: at no time could infectious virus be recovered from the lungs of infected animals. The ease with which attenuated virus candidates can be produced and administered favors their further development as vaccines to combat the ongoing pandemic. Vaccine design 90 Our goal was to generate attenuated SARS-CoV-2 vaccine candidates through large-scale 91 recoding of the SARS-CoV-2 genome by CPD (Coleman et al., 2008; Kunec and Osterrieder, 92 2016). To achieve virus attenuation in humans, we recoded the genome of SARS-CoV-2 with 93 codon pairs that are the most underrepresented in human genes (Kunec and Osterrieder, 94 2016). The genetically modified SARS-CoV-2 mutants were produced using a recently 95 established reverse genetics system of SARS-CoV-2 (Thi Nhu Thao et al., 2020) (Figure 1 ). 96 The system relies on 12 subgenomic fragments of the SARS-CoV-2 genome, which are 97 assembled into a single yeast/bacterial artificial chromosome (YAC/BAC) by transformation-98 associated recombination (TAR) cloning in Saccharomyces cerevisiae (Noskov et al., 2002) . 99 The subgenomic fragments are approximately 3,000 bp long, and the neighboring fragments To preserve the full compatibility with the available reverse genetics system, we recoded only 103 SARS-CoV-2 sequences that were not present in the overlapping parts of the subgenomic 104 fragments (approximately 2,500 bp in each recoded fragment) (Figure 1, Table S1 ). This 105 design enabled us to generate a wide variety of SARS-CoV-2 mutants, carrying a single or 106 more recoded fragments. 107 We recoded nine fragments of the SARS-CoV-2 reverse genetics system (fragments 2-10). 108 Fragments 1 and 12, which are relatively short, 591 and 1,812 bp respectively, and fragment 109 11, which contains many short ORFs, were excluded from the recoding. To ensure that mutant 110 viruses are replication-competent, two genomic regions containing essential cis-acting RNA 111 elements were excluded from the recoding: the frame-shifting element carried by fragment 6 112 and the transcription regulatory sequence (TRS) of the spike gene within fragment 9. In 113 addition, the first 500 bp of ORF 1a located in fragment 2 were not recoded either. The 114 characteristics of the parental and recoded sequences are summarized in Table S1 . 115 116 We attempted to rescue infectious progeny from the recoded SARS-CoV-2 constructs by two 117 different methodsdirectly from DNA in Vero E6 cells and from viral RNA in BHK-21 118 cells. To enable recovery from DNA, the genome of the SARS-CoV-2 was placed under the 119 control of the immediate-early promoter of the human cytomegalovirus. Despite multiple 120 attempts, we were able to rescue infectious progeny viruses from only two out of eight 121 recoded SARS-CoV-2 constructs, and the rescue occurred only by means of RNA 122 transfection. We rescued infectious viruses that carried recoded fragments 2 and 6 (thereafter 123 labeled as CPD2 and CPD6). It is known that extensive recoding by CPD can lead to a lethal 124 phenotype of recoded mutants (Coleman et al., 2008; Eschke et al., 2018) . We suspected that 125 the extent of recoding in constructs that did not produce infectious viruses was too high and, 126 therefore, constructed additional mutants with shorter deoptimized sequences (Figure 1 , 127 Table S1 ). In total, we engineered six SARS-CoV-2 mutant constructs that carried shorter, 128 approximately 1,000 bp-long recoded sequences (sCPD3, sCPD4, sCPD5, sCPD8, sCPD9, 129 and sCPD10). As predicted, reducing the extent of deoptimization led to the rescue of several To assess the genetic stability of the recoded viruses, we passaged the two most attenuated 152 viruses sCPD9 and sCPD10 serially 10 times in Vero E6 cells at a multiplicity of infection 153 (MOI) of 0.1. After 10 passages, the viruses did not appear to have undergone notable 154 phenotypic changes, as they still produced only small foci on Vero E6 cells and did not 155 produce readily observable CPE within 72 hpi. We also analyzed the genomes of the passaged 156 viruses by RT-PCR and Sanger sequencing, and we did not detect any mutations in the 157 recoded regions. (Figure 1) , it is expected to produce comparatively less spike protein than either the WT or 167 sCPD9 viruses. Indeed, spike protein production was significantly reduced in cells infected 168 with sCPD10 virus compared with cells infected with WT or sCPD9 viruses (Figure S2) , 169 indicating that CPD reduced protein production of the target gene. Three animals of each group were euthanized on day 3 after vaccination, and on day 23, 24, 179 26 and 35 after vaccination (day 2, 3, 5 and 14 after challenge) to determine the degree of 180 virus replication in different organs and to assess pathological changes in the lungs. Due to space limitations, we examined the attenuation of 5 recoded viruses in two animal 182 trials. In the first trial, hamsters were vaccinated with 1 × 10 5 FFU of the recoded viruses 183 CPD6, sCPD3, or sCPD4. In the second trial, hamsters were vaccinated with 1 × 10 4 FFU of 184 the recoded viruses sCPD9, or sCPD10, a 10-fold lower dose than in the first vaccination trial. 185 We used a lower dose because initially we were unable to grow the sCPD9 and sCPD10 186 mutants to sufficiently high levels, as the peak titers of these mutants in Vero E6 cells were 187 10-100 times lower than those of the parental virus ( Figure 2B ). Roborovski dwarf hamsters were randomly assigned to two groups. Twelve hamsters were 326 mock-infected and 30 hamsters were infected with 1×10 5 FFU of the mutant virus sCPD9. Body weight and body temperature were recorded daily for the duration of the experiment (21 328 days). On average, the sCPD9-infected hamsters lost only little weight on day 1 (3.4%), but 329 began to gain weight already on day 2 and continued to gain weight steadily until the end of 330 J o u r n a l P r e -p r o o f the experiment ( Figure 7A ). Individual hamsters either lost up to 8.0% weight or gained up to 331 3.6% weight on day 1 after infection. The mock-infected hamsters did not gain weight during 332 first 3 days after mock infection, but gained weight precipitously on day 4 and steadily 333 thereafter. Daily weight gains were comparable between the two groups, and at the end of this 334 experiment, on day 21, both groups showed comparable weight distribution ( Figure 7A ). 335 Note that daily weight averages show greater variation in the case of mock-infected hamsters, The main disadvantage of live attenuated virus vaccines is the risk of reversion to virulence. For example, the oral poliovirus vaccine has 51 mutations, but only 5 of them are attenuating. As a result, this vaccine is prone to reversion, and in rare cases it reverted to virulence and Our data demonstrate that a single-dose vaccination with CPD6, sCPD9 or sCPD10 viruses 506 protects vaccinated hamsters from developing disease after challenge infection with WT 507 SARS-CoV-2 (Figure 3-7) . This was evidenced by histological evaluation of lung pathology, (Figure 5F ). 515 The amount of viral RNA detected in the lungs of challenged animals was very low on days 2, 516 3 and 5 after the challenge, and, more importantly, we could not isolate a replicating virus 517 from the lungs of the animals after challenge infection (Figure 3K-P) . Our data thus show 518 that, although recoded viruses were unable to protect the upper respiratory tract from 519 reinfection with the virulent WT virus, they did protect the lower respiratory tract very well 520 from infection. 521 We surmise that a single-dose vaccination with a live modified attenuated virus should 522 provide protective immunity against the infection with pathogenic SARS-CoV-2, as we were 523 unable to detect infectious virus particles in the lungs of any of the vaccinated animals. In summary, of all the engineered live attenuated viruses tested, sCPD9 showed the best 551 balance between attenuation, safety, immunogenicity and protective efficacy. We believe that 552 the safety, immunogenicity and vaccine efficacy of this candidate should be investigated in 553 different animals, non-human primates and possibly also humans. 555 We thank Ann Reum, Annett Neubert, Angela Linke and Michaela Scholz for excellent 556 technical assistance. We thank Sven Reiche, Friedrich-Loeffler-Institut for providing anti-557 SARS-CoV-2 nucleocapsid antibody. We thank Christa Thöne-Reineke for expert support in 558 animal welfare and husbandry and Carfil Inc. for their support of our animal husbandry. We 559 thank Christian Drosten for bringing together the scientific groups involved in this study. This CoV-2 genome correspond to the SARS-CoV-2 reference sequence NC_045512.2. The coding sequences of SARS-CoV-2 were recoded by CPD (Coleman et al., 2008) . CPD Germany). For overviews with lower magnification, slides were automatically digitized using 836 the Aperio CS2 slide scanner (Leica Biosystems Imaging Inc., Vista, CA, USA) and image 837 files were generated using the Image Scope Software (Leica Biosystems Imaging Inc.). COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use -First Single-870 Shot Vaccine in Fight Against Global Pandemic The World Health Organization. Draft landscape of COVID-19 candidate vaccines Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants Engineering the largest RNA virus genome as an infectious bacterial artificial chromosome Safety and Immunogenicity of 881 SARS-CoV-2 mRNA-1273 Vaccine in Older Adults Efficacy and Safety of the mRNA-1273 SARS-CoV-2 884 Vaccine A brief history of the prevention of infectious diseases by immunisations. 886 Comparative immunology, microbiology and infectious diseases Evaluation of the attenuation, immunogenicity, and efficacy of a live virus vaccine generated by 889 codon-pair bias de-optimization of the 2009 pandemic H1N1 influenza virus, in ferrets A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating 893 person-to-person transmission: a study of a family cluster Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia 896 in Wuhan, China: a descriptive study Virus 898 attenuation by genome-scale changes in codon pair bias Evaluation of the mRNA-1273 Vaccine against 901 SARS-CoV-2 in Nonhuman Primates Detection of 2019 novel coronavirus (2019-nCoV) by 904 real-time RT-PCR BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass 907 Vaccination Setting An interactive web-based dashboard to track COVID-19 in 909 real time Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, 912 BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month 913 follow-up of a double-blind Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against 916 SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised 917 controlled trial Attenuation of a very virulent Marek's 919 disease herpesvirus (MDV) by codon pair bias deoptimization Development of an inactivated vaccine candidate for SARS-CoV-2 Hospitalization Rates and Characteristics of Patients 924 Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 -COVID-NET, 14 States Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination Mechanism of Virus Attenuation by Codon Pair 930 Deoptimization Standardization of Reporting Criteria for Lung Pathology in 933 SARS-CoV-2 Infected Hamsters -What Matters? Impact and effectiveness of mRNA BNT162b2 vaccine against 936 SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide 937 vaccination campaign in Israel: an observational study using national surveillance data COVID-19 vaccine coverage in health-care workers in England and 940 effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, 941 cohort study An mRNA Vaccine 944 against SARS-CoV-2 -Preliminary Report Vaccine-946 derived polioviruses and the endgame strategy for global polio eradication Codon Pair Bias Is a Direct Consequence of Dinucleotide Bias Vaccine Strategies. In Encyclopedia of Virology SARS-CoV and SARS-CoV-2 are transmitted through the air between 955 ferrets over more than one meter distance Codon usage determines the 957 mutational robustness, evolutionary capacity, and virulence of an RNA virus Rationalizing the development of live attenuated 960 virus vaccines Attenuation of human respiratory syncytial virus by 963 genome-scale codon-pair deoptimization Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: 967 an interim analysis of a randomised controlled phase 3 trial in Russia Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine 970 against the B.1.351 Variant China's COVID vaccines are going global -but questions remain Live attenuated influenza virus vaccines by computer-aided rational design. 974 Phase I/II study of COVID-19 RNA vaccine BNT162b1 in 977 adults Effects of a mixture of medetomidine, midazolam and butorphanol on 980 anesthesia and blood biochemistry and the antagonizing action of atipamezole in hamsters A 983 genetic system for direct selection of gene-positive clones during recombinational cloning in yeast The role of ZAP and OAS3/RNAseL pathways in the attenuation of an RNA 987 virus with elevated frequencies of CpG and UpA dinucleotides Age-Dependent Progression of SARS-CoV-2 990 Infection in Syrian Hamsters Attenuation of Viruses by Large-Scale Recoding of their 992 Genomes: the Selection Is Always Biased Safety and Efficacy of the BNT162b2 mRNA 995 Covid-19 Vaccine COVID-19 vaccine BNT162b1 elicits human antibody and TH1 998 T-cell responses NIH Image to ImageJ: 25 years of image 1000 analysis Large-scale recoding of an arbovirus genome to rebalance its insect 1003 versus mammalian preference Pathogenesis and transmission of SARS-CoV-2 virus in golden Syrian hamsters Immunogenicity 1008 and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP Identification of two functionally redundant RNA elements in the coding sequence of 1012 poliovirus using computer-generated design Rapid reconstruction of SARS-CoV-2 using a synthetic 1015 genomics platform The Roborovski dwarf hamster -a highly susceptible model 1018 for a rapid and fatal course of SARS-CoV-2 infection Safety and efficacy of the ChAdOx1 nCoV-1021 19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials 1022 in Brazil, South Africa, and the UK Single-dose administration and the 1025 influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 1026 (AZD1222) vaccine: a pooled analysis of four randomised trials Safety and Immunogenicity of Two RNA-Based 1029 Covid-19 Vaccine Candidates Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection 1032 against SARS-CoV-2 Synthetic viruses: a new 1034 opportunity to understand and prevent viral disease Virological assessment of hospitalized patients with 1037 COVID-2019 Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating 1040 in China Deliberate reduction of 1042 hemagglutinin and neuraminidase expression of influenza virus leads to an ultraprotective live vaccine 1043 in mice 1045 (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy 1046 adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial 1049 (2020a). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, 1050 China: a retrospective cohort study A pneumonia outbreak associated with a new coronavirus of probable bat origin Immunogenicity and safety of a recombinant adenovirus type-5-vectored 1056 COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-1057 controlled, phase 2 trial Coronavirus Vaccine Tracker. The New York Times SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients